Nacubactam: a review on mechanistic insights and therapeutic promise for combating β-lactam resistance among multidrug-resistant Gram-negative pathogens
Dharmender Kumar, Narinder Kaur, Surender, Shahbaz Aman, Ayesha Bibi · 2026
Read Nacubactam: a review on mechanistic insights and therapeutic promise for combating β-lactam resistance among multidrug-resistant Gram-negative pathogens by Dharmender Kumar, Narinder Kaur, Surender, Shahbaz Aman, Ayesha Bibi (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13236190.txt.
Description
Dharmender Kumar and four co-authors review a drug helper that may restore the power of common antibiotics. Many harmful bacteria now resist beta-lactam drugs by making enzymes that break them. Nacubactam is a newer blocker that stops several of those enzymes. Their 2026 review sums up how the drug works and what lab and early human tests show. It also binds a key cell-wall protein, which adds its own bacteria-killing effect.
Paired with drugs such as cefepime or meropenem, it sharply cut the dose needed against hard-to-treat germs in lab tests. Early trials in people found it well tolerated. The review notes gaps: it does not directly beat one major enzyme class, and large patient trials are still scarce. More clinical proof is needed.
Catalog record
| CREATOR | Dharmender Kumar, Narinder Kaur, Surender, Shahbaz Aman, Ayesha Bibi |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 51 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |